XML 44 R35.htm IDEA: XBRL DOCUMENT v3.26.1
Segment information - Significant Segment Expenses (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Indirect research and development expenses:        
Total research and development expenses $ 3,923 $ 7,953 $ 7,516 $ 16,243
Research and Development of Immunotherapies and Vaccines        
Direct research and development expenses:        
Total direct research and development expenses 3,442 4,710 6,344 8,202
Change in direct research and development expenses (1,268)   (1,858)  
Indirect research and development expenses:        
Total indirect research and development expenses 481 3,243 1,172 8,041
Change In indirect research and development expenses (2,762)   (6,869)  
Total research and development expenses 3,923 7,953 7,516 16,243
Change in research and development expenses (4,030)   (8,727)  
Research and Development of Immunotherapies and Vaccines | Personnel-related (including share-based compensation)        
Indirect research and development expenses:        
Total indirect research and development expenses 440 2,450 979 6,394
Change In indirect research and development expenses (2,010)   (5,415)  
Research and Development of Immunotherapies and Vaccines | Facility related        
Indirect research and development expenses:        
Total indirect research and development expenses 15 350 102 685
Change In indirect research and development expenses (335)   (583)  
Research and Development of Immunotherapies and Vaccines | Other indirect costs        
Indirect research and development expenses:        
Total indirect research and development expenses 26 443 91 962
Change In indirect research and development expenses (417)   (871)  
Research and Development of Immunotherapies and Vaccines | VTP-1000 Celiac        
Direct research and development expenses:        
Total direct research and development expenses 2,936 1,782 4,358 2,764
Change in direct research and development expenses 1,154   1,594  
Research and Development of Immunotherapies and Vaccines | Barinthus legacy assets        
Direct research and development expenses:        
Total direct research and development expenses 506 $ 2,928 1,986 $ 5,438
Change in direct research and development expenses $ (2,422)   $ (3,452)